 mich sentiment jul prelim cs
polici report congress ahead
chair powel testimoni juli
cs pharmafilt -- watch revis estim
model mainten lower estim target price
leg stand sell-off overdon rais estim
remain bullish bx kkr top long due fundrais outlook potenti c-corp convers revis estim
missouri verdict like increas attent product liabil lawsuit
physician fee schedul propos rule highlight effort reduc clinician burden
infrastructur insight hospit capital-expenditure us ir
write wall wallboard survey
quarterli investor sentiment survey view investor sentiment ahead
analyst disclosur credit suiss seek busi compani cover research
report result investor awar firm may conflict interest could affect
object report investor consid report singl factor make invest
cs pharmafilt -- watch revis estim
progress new product outcom strateg review like focu us pharma earn kick
next week report tuesday follow rest larg cap compani follow two week
addit usual interest uptak key recent launch product develop import mid-lat
stage asset expect signific focu confer call outcom strateg review
reorgan announc variou compani busi develop prioriti
compani given time assess impact us corpor tax reform note present
updat model head result base analysi latest
prescript price trend maintain rate target price larg cap compani
outperform target price tuesday juli eastern releas call dial-in
sale cs ep cs continu under-perform
broader market look next week earn releas confer call visibl
current growth driver outlook rest pharma segment like face
addit top-line pressur remain confid outlook key product darzalex imbruvica xarelto
well newer product tremfya erleada also look see biosimilar competit impact
remicad difficult product recent consum medic devic busi review day
provid us reason long-term optim two segment also look next week call see
sign improv perform either segment take pressur
pharma first earn call new cfo also first sinc manag chang
announc last month look color chang impact strategi go forward
passcod sale cs ep cs acknowledg
reason increas optim diabet non-diabet part busi remain cautiou
ahead data trulic rewind cardiovascular cv outcom trial top-line data expect earli
believ chanc show superior reduc cardiovascular event
model mainten lower estim target price
lower ep estim target price follow june aum result revis revenu expens aum roll
assumpt lower adjust ep estim accordingli target
price move deriv multipl cash ep estim risk includ uk
flow follow weaker perform global target return flow gener near zero return
last three year vs libor object
receiv product pleas specifi credit suiss contact email call
leg stand sell-off overdon rais estim
over-correct quarter disappoint market stock wednesday weak growth
aviat servic y/i guidanc neg disclosur investig doj
weigh sentiment think concern first two point myopic larg without merit though doj
investig offer yet unmeasur risk similar exposur face investig
ultim believ power stori top-line enter meati growth cycl model
growth driven expeditionari servic inl contract ramp also
remain bullish end-market particularli busi continu deriv benefit strong
traffic growth global ytd north america ytd part trade busi receiv dual tailwind
higher traffic lag retir latter help on-going engin issu new aircraft slow pace
retir could place suppli constraint fewer aircraft part-out larg mitig
scale abil out-compet come market
result revenu y/i miss consensu strong growth es y/i inl contract
ramp off-set weaker growth y/i due wind-down cl program y/i
well tough comp year ago period gross margin tick quarter y/i es
margin sg expens elev sale includ sever
restructur expens well higher stock base compens expens due strong run-up share
ep continu oper ahead consensu help lower effect tax rate
estim revis estim rise respect introduc
estim tp remain valu multipl discount peer ep reiter
outperform risk includ inabl sourc new engin part end-market weak wage inflat
market close yesterday wft announc sign agreement sale land
rig algeria kuwait saudi arabia iraq per rig iraq wft sell two idl rig
algeria kuwait saudi arabia sale oper busi leav rig remain view
major valu come chunk rig announc yesterday land rig ebitda impli
valu remain rig point total valuat land rig ebitda
estim busi market close share time write first shoe
drop expect anoth non-cor asset sale suspect core analysi busi
next asset sold estim valuat reiter outperform rate
price target wft upsid potenti yesterday close price note wft bring bacon
juri earlier week sandbox unit lawsuit arrow llc sandbox logist
receiv unanim verdict twelv issu present lawsuit juri found arrow breach
confidenti non-disclosur agreement sandbox arrow founder ceo john allegretti
person breach settlement agreement commit fraud sandbox final amount damag
yet confirm trial court juri award monetari damag sandbox total
note monetari fine huge amount lawsuit mark broader win sandbox competitor
last mile logist sand space
first impress top notch cactu earlier week launch share offer close
monday close price deal announc compani also gave guidanc
file expect revenu midpoint vs consensu vs
ebitda midpoint vs consensu vs impli
ebitda margin midpoint vs street impli
adjust bhge catch compani tweak ebitda
make chang price target risk thesi includ global demand global oil ga recoveri
oil price
receiv product pleas specifi credit suiss contact email call
top food chain week host dinner follow day meet dalla ceo jeremi
thigpen investor focu center around outlook harsh environ ultra-deepwat
udw market overal deepwat market outlook pace recoveri dayrat manag see rate
move higher next year materi move higher state balanc sheet follow recent
seri secur deal stock done well low mid-march versu diamond off-shore drill
lever name ensco/nobl remain top rel pick off-shore driller
owe backlog norwegian nsea exposur drive out-performance prolong recoveri scenario
leverag high spec udw rate option valu help close perform gap versu esv/n
 outlook readi buy slim pick topic remain key investor focu
top incom investor question given strong near-term liquid position-manag continu
opportunist market remain firm remain newbuild mostli spoken point
expect much near-term outsid possibl buy-out remain portion norg jv view
event notabl manag take closer look buy udw side despit lead edg dayrat still
around cash break-even gom today afford cash flow visibl earli next
decad cash flow backlog would expect announc particularli uncontract
udw asset result near-term drop stock price would use opportun consid ad rel
estim ep estim move updat downtim activ
assumpt risk includ oil price capital-expenditure rig oversuppli
remain bullish bx kkr top long due fundrais outlook potenti c-corp
convers revis estim target price
result expect solid fundrais mix econom net incom accru carri trend lower
expect distribut earn soft invest activ quarter beyond preliminari outlook
includ stronger invest activ bx kkr continu robust fundrais level research note updat
estim target price across coverag apo bx mdli
long-term industri outlook reiter posit lt view industri given increas interest long-onli
investor kkr potenti bx continu strong fundrais environ illiquid alt steal share
tradit institutions/retail investor increas alloc lp consolid relationship potenti russel
addit next summer kkr bx minor tweak corpor govern legal structur convers
potenti c-corp convers bx think altern could convert c-corp structur
next five year
long-term stock view -- bx kkr top long look bx convert c-corp next year
could convert soon thursday result addit bx divers robust fundrais outlook
driven next privat equiti fund bcp real estat fund brep newer busi
insur infrastructur core plu real estat also look convert legal structur up-c
would help stock improv long-onli passiv ownership russel still rate kkr buy like
long-term growth stori howev recent out-performance us slightli less bullish stock today
result -- near-term expect look strong fundament result kkr benefit share
price next day look mix result bx eni beat de miss firm announc c-corp
convers result think stock could rise place probabl around time
would line-up perfectli front bx septemb investor day also think kkr success could acceler bx
timelin convert look weaker rel result apollo eni miss cg eni miss
receiv product pleas specifi credit suiss contact email call
missouri verdict like increas attent product liabil lawsuit
larg number on-going litig gain attent receiv increas number investor inquiri
recent month numer talcum mesh lawsuit current defend expect increas
follow news missouri juri award compensatori punit damag women
famili trial focus talc powder product potenti link ovarian cancer alreadi announc plan
appeal given number case relat talc mesh size potenti verdict challeng
put reason rang ultim liabil may turn lay publicli avail
front note given strong financi posit confid abl absorb even rel larg
payment resolv case
outcom major talc case favor number talc-rel case gone significantli recent
month decemb march damag unfavor talc verdict high
rel mesh per case even today verdict abl overturn
mesh settlement like econom may come sooner decis settl vast major
mesh case mesh litig come end may also help spark increas investor
interest issu relat unlik slower engag larg mesh settlement
settl case averag compani cost use rang outstand case could
cost settlement although uncertainti around juri verdict could lead cost
substanti
believ solid pc shipment data strongest unit growth sinc driven commerci refresh cycl
suggest potenti upsid cs/street comput estim y/i
y/i expect window revenu share declin steadili believ pc strength bode well
continu oper incom growth cash flow gener
window refresh cycl solid pc shipment data unit y/i q/q ahead histor
season q/q cs estim unit suggest continu underli strength pc believ
healthi enterpris spend cycl combin win refresh continu gener strong demand commerci pc
across multipl geographi america emea apac see potenti upsid window revenue estim
y/i well estim y/i also view on-going pc refresh cycl
potenti catalyz adopt offic
mix improv also encourag improv shipment mix strong perform premium-notebook
game pc see high-end strength drive strong window oem perform non- oem revenu
continu impact price pressur entri level point market
strength public sector also attribut strong commerci volum healthi us fed educ sector demand
well major dept educ project apac see educ sector battleground rise import
attempt regain momentum chromebook new product releas low-pric surfac go
receiv product pleas specifi credit suiss contact email call
laid june board bia toward independ struggl soup bode poorli stock price
report believ campbel board choos maintain compani independ end strateg
review rather take activist investor third point suggest sell compani find hard believ
dorranc famili would decid sell compani stock high seven month
sinc made transform acquisit snyder s-lanc boost growth rate portfolio view recent
hire two senior sc johnson execut roberto leopardi may diego palmieri two day ago small
logic data point support view
take true campbel opportun repres win-win scenario execut whether campbel sell
think fair assum mr palmieri mr leopardi join compani intent return
growth oper event sale stock receiv compens long-term
incent sacrif sc johnson goe mayb change-in-control premium
execut turnaround next year help stock regain peer multipl stock might get back all-
time high near execut accumul stock along way campbel interim ceo
board member keith mclaughlin certainli give assur whether dorranc family-control
board decid sell howev hire mr palmieri two day ago think fair assum
maintain person view campbel remain independ two execut year
experi family-control sc johnson repres good fit campbel corpor cultur
earlier today bloomberg report narrow two competitor credit card portfolio
 see wal-mart weigh bid capit one credit card current contract belong
expect expir believ like retain contract also believ ideal
partnership take
like retain contract largest player privat label bn receiv
end would note gener custom larg cabela portfolio
high-qual co-brand portfolio size portfolio last larg privat label program
compani sold citi happi defer interest featur
long-tim player non-prime card busi believ slowdown organ growth past
month reaction non-prim concentr portfolio think less like would
comfort acquir larg portfolio potenti signific non-prime compon portfolio
particularli underwrit loan believ lower probabl buyer citi
cover bid last time contract rfp ed like case retain contract compani
like cede econom term profit share
receiv product pleas specifi credit suiss contact email call
physician fee schedul propos rule highlight effort reduc clinician burden
modest rate impact expect specialti juli market close releas propos
rule physician fee schedul propos net updat compris updat factor
requir law partial off-set budget neutral adjust compar net updat
impact updat vari specialti propos updat anesthesiolog emerg
medicin radiolog vs respect propos ob/gyn pediatr
get updat
exposur medicar evhc md evhc earn revenu medicar md disclos
simpli earn revenu govern sourc medicar servic line evhc
produc revenu ed/hospitalist anesthesiolog radiolog children
servic md produc revenu anesthesiolog neonatolog pediatr
maternal-fet medicin radiology/teleradiolog
emphas effort limit clinician paperwork strengthen physician/pati relationship propos rule
includ sever propos gear toward increas flexibl limit administr burden clinician also
propos pay separ virtual check-in remot evalu record video imag final made
updat qualiti payment program qpp vehicl macra implement includ remov process-
base qualiti measur also ad opportun waiv mip requir clinician particip new
would test whether waiv mip requir would increas level particip payment arrang
similar advanc apm
clinic lab -- revisit definit applic lab lab industri advoc broaden definit
applic lab pama lab would requir report commerci price data use
creat clf rate within propos rule said consid exclud payment total medicar revenu
calcul whether lab applic lab pama could increas number report lab
howev think would materi impact clf rate sinc largest lab alreadi
includ weighted-averag median also ask feedback altern approach defin applic
lab use clia certif number chang low expenditur threshold compon definit
broaden definit applic lab could posit nation lab
infrastructur insight hospit capital-expenditure us ir
report focu start carolina carneiro initi latam util engi brazil team
top pick indonesia jahja initi pt medikaloka hermina heal jk/heal ij
second-largest privat hospit chain asian team rais target price ck infrastructur power asset
hold limit clp hold limit hong kong electr invest michael
weinstein first solar nextera energi partner nep target increas
us ir extend solar invest tax credit
upgrad posit rate action canadian team upgrad brookfield infrastructur partner bip outperform
prior neutral rate us team upgrad eversourc energi es neutral previou
downgrad notabl downgrad came australian transport infrastructur
downgrad sydney airport syd ax under-perform neutral util downgrad spark
infrastructur group ski ax under-perform neutral final canadian team downgrad hydro one
receiv product pleas specifi credit suiss contact email call
write wall wallboard survey
residenti construct remodel activ drive demand order better gaug suppli demand condit
within wallboard industri survey manufactur distributor across survey result found
healthi level demand end specif produc saw revenu rise year year
experienc gain among distributor saw expans full year major
group forecast top-lin gain rang addit manufactur distributor look
averag growth especi storm ravag southern market said note industri gener struggl
trade-off volum price
price power hold though gain could off-set inflat quarter manufactur
distributor saw price gain rang compar announc price increas earlier year
back manufactur announc addit round price similar magnitud last one
like attempt make margin loss line channel check respond anticip cost
inflat year come transport pressur intensifi averag flatb truck rate/mil
year year quarter
competit like remain elev limit price realiz manufactur distributor
cite higher level competit last quarter major expect hold
year given region natur wallboard busi low util rate height competit could
impact profit note consolid distribut channel could limit success manufactur
put togeth -- maintain neutral stanc usg despit benefit strong volum potenti price
realiz expect stock rang bound close acquisit knauf target price line
takeout valuat base ebitda estim vs group averag risk includ
failur complet merger high degre industri competit
quarterli investor sentiment survey view investor sentiment ahead
survey investor respond long-onli investor hedg fund
investor larg mco ing expect like ci
like miss head earn investor respond expect mco averag beat expect
compar expect beat head believ pick-up expect driven two
factor head flu impact unclear seen major risk earn
report solid necessarili let beat flow full year guidanc rais impli
outlook rest year reason conserv seen investor like exceed
expect highest percentag manag care name flip side ci
seen like miss expect believ sentiment around ci primarili driven confus
around compani intra-quart split commentari
view relat amazon move healthcar investor see move healthcar
signific factor consid invest healthcar space anoth say watch
develop someth made chang posit within space major
investor see retail pharmaci subsector threaten amazon purchas pillpack anoth
see amazon move threat pbm separ roughli investor respond expect amazon focu
next year build pillpack market posit anoth investor believ amazon acquir
anoth compani within drug suppli chain
view relat mid-term elect investor see mid-term elect like ad modest volatil
healthcar stock like chang overal view healthcar space respect potenti
outcom mid-term elect investor believ republican maintain control hous senat
best outcom healthcar stock
view relat commerci price risk roughli two-third investor see possibl price pressur develop
commerci risk market legitim concern see littl evid actual occur
point fact investor respond see issu overblown concern invest commun
littl evid
favorit sectors/stock diversifi manag pick favorit healthcar servic sector
highest number investor follow medicaid manag also unchang ask favorit
subsector healthcar overal manag pick highest number investor vs spot
survey follow small mid-cap unchang survey medic devic equip
vs spot survey
receiv product pleas specifi credit suiss contact email call
headlin price previou day close unless otherwis note
compani mention price jul
kkr co lp kkr outperform tp
labcorp america lh outperform tp
receiv product pleas specifi credit suiss contact email call
